Initiating Treatment
Active Resources: 11
-
The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and treatable.
Type: Articles, Reports, and ManualsPublish Date: 4/15/2021 -
The National HIV Curriculum (NHC) offers free online continuing education for novice-to-expert health professionals, students, and faculty.
Type: Online and Self-Paced LearningPublish Date: 9/14/2020 -
Slides from a 1-day course for primary care physicians and mid-level clinicians, which combines the latest research with current treatment guidelines for managing patients with HIV.
Type: Training MaterialsPublish Date: 7/31/2020 -
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection.
Type: Training MaterialsPublish Date: 3/1/2020 -
Excerpt from the Guidelines Introduction: "The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of
Type: GuidelinesPublish Date: 12/18/2019 -
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment.
Type: Online and Self-Paced LearningPublish Date: 12/4/2019 -
In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S.
Type: Clinical Reference ToolsPublish Date: 6/10/2019 -
This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely.
Type: Clinical Reference ToolsPublish Date: 2/20/2019Review Date: 2/20/2019 -
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day as the H
Type: GuidelinesPublish Date: 2/14/2019 -
Seven popular clinical resources covering HIV testing, prevention (PrEP and PEP), rapid ART, and HIV primary care, to be used in diverse clinical settings.
Type: Clinical Reference ToolsPublish Date: 12/11/2018 -
To help HIV care providers engage patients in care and transmission prevention, the Centers for Disease Control and Prevention (CDC) developed a new and comprehensive Prevention IS Care re
Type: Clinical Reference ToolsPublish Date: 5/17/2016Review Date: 2/20/2019
Archive Resources: 3
-
Approximately 7/10 people with HIV in the U.S. are not virally suppressed.
Type: Clinical Reference ToolsPublish Date: 1/28/2015 -
The AETC Program national, regional, and local partners are a part of the HRSA-funded Ryan White HIV/AIDS Program.
Type: Clinical Reference ToolsPublish Date: 6/1/2013Review Date: 1/11/2017 -
After HIV diagnosis, timely entry into HIV medical care and retention in that care are essential to the provision of effective antiretroviral therapy (ART).
Type: GuidelinesPublish Date: 3/5/2012Review Date: 5/17/2019
Articles: 5
-
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...
-
Immediate ART Initiation: Guide for Clinicians
Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "...
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...